Shire: Remodeling Specialty Pharma

As biotech and Big Pharma invade spec pharma's traditional in-licensing ground, Shire's challenge is to bring investors along with its necessary strategic evolution. They've succeeded so far. Other spec pharma firms should take note of how.

By Melanie Senior

Matt Emmens, CEO of Shire Pharmaceuticals Group PLC , described last year's acquisition of Transkaryotic Therapies Inc. (TKT) as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo